Novavax Q3 2026 net loss narrows 84% to $31.38 million

Bitget2026/11/05 13:05

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Novavax's third-quarter 2026 net loss narrowed 84% to $31.38 million, while revenue slipped to $68.3 million.
R&D expenses fell 47% to $52.45 million, partly due to near-completion of Sanofi clinical support for Nuvaxovid.
October brought a $125 million milestone payment triggered by Sanofi's launch of a Phase 3 influenza-COVID-19 combination vaccine trial in Europe.
Full-year 2026 combined R&D and SG&A expense guidance narrowed to $375 million–$395 million.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Novavax Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202611050800PR_NEWS_USPR_____PH89697) on November 05, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Novavax Q3 2026 net loss narrows 84% to $31.38 million

You may also like

Crypto prices